adalimumab
Selected indexed studies
- AVT02: An Adalimumab Biosimilar. (Clin Drug Investig, 2022) [PMID:36181655]
- FKB327: An Adalimumab Biosimilar. (BioDrugs, 2019) [PMID:30712241]
- Navigating adalimumab biosimilars: an expert opinion. (J Comp Eff Res, 2023) [PMID:37855223]
_Worker-drafted node — pending editorial review._
Connections
No connections recorded yet.
Sources
- AVT02: An Adalimumab Biosimilar. (2022) pubmed
- FKB327: An Adalimumab Biosimilar. (2019) pubmed
- Navigating adalimumab biosimilars: an expert opinion. (2023) pubmed
- PF-06410293: An Adalimumab Biosimilar. (2020) pubmed
- Adalimumab for CNS sarcoidosis: single-center experience and literature review. (2022) pubmed
- GP2017: An Adalimumab Biosimilar. (2018) pubmed
- Adalimumab for the treatment of uveitis. (2017) pubmed
- SB5: An Adalimumab Biosimilar. (2018) pubmed
- Adalimumab-Adbm: The First Interchangeable Biosimilar for the Treatment of Inflammatory Diseases. (2022) pubmed
- Adalimumab Biosimilars in Europe: An Overview of the Clinical Evidence. (2019) pubmed